Colson Y L, Li H, Boggs S S, Patrene K D, Johnson P C, Ildstad S T
Department of Surgery, University of Pittsburgh, PA 15261, USA.
J Immunol. 1996 Oct 1;157(7):2820-9.
For over 40 years, the association between hemopoietic chimerism and donor-specific tolerance for allografts has been recognized. However, toxicity associated with lethal conditioning has prevented the clinical application of bone marrow (BM) chimerism to induce tolerance. We previously demonstrated that engraftment could be achieved with less than total recipient myeloablation (700 cGy) and that the incidence of engraftment correlated with the dose of total body irradiation (TBI). Administration of cyclophosphamide (CyP) on Day +2 reduced the minimum TBI dose sufficient to permit engraftment to 500 cGy. In the current study, addition of antilymphocyte globulin (ALG) to the TBI/CyP-based conditioning approach reduced the radiation required for engraftment to < or = 300 cGy. B10 (H-2b) mice conditioned with ALG on day -3, 300 cGy of TBI with transplantation of B10.BR (H-2k) or BALB/c (H-2d) BM on day 0, and CyP on day +2 exhibited evidence of donor chimerism (49.6 +/- 3.7% and 38.2 +/- 2.4%, respectively) in 97% of recipients. ALG eliminated CD4+ and CD8+ cells and decreased NK1.1+ cells in the peripheral circulation at the time of transplantation. Moreover, T and NK cells in the host BM were significantly decreased compared with cells of recipients conditioned with TBI alone. CyP delayed repopulation of host thymocytes, providing time for the establishment of donor chimerism before production of mature T cells. Chimeric animals exhibited stable multilineage chimerism and donor-specific tolerance to skin grafts and in in vitro assays. This model may provide a clinically acceptable approach for the induction of donor-specific transplantation tolerance.
四十多年来,造血嵌合体与同种异体移植物的供体特异性耐受之间的关联已得到认可。然而,与致死性预处理相关的毒性阻碍了骨髓(BM)嵌合体在诱导耐受方面的临床应用。我们先前证明,采用少于全量受体骨髓消融(700 cGy)即可实现植入,且植入发生率与全身照射(TBI)剂量相关。在第+2天给予环磷酰胺(CyP)可将足以允许植入的最低TBI剂量降至500 cGy。在当前研究中,在基于TBI/CyP的预处理方案中添加抗淋巴细胞球蛋白(ALG)可将植入所需的辐射剂量降至≤300 cGy。在第-3天用ALG预处理、第0天接受300 cGy TBI并移植B10.BR(H-2k)或BALB/c(H-2d)骨髓、第+2天给予CyP的B10(H-2b)小鼠,97%的受体出现供体嵌合体证据(分别为49.6±3.7%和38.2±2.4%)。移植时,ALG消除了外周循环中的CD4+和CD8+细胞,并减少了NK1.1+细胞。此外,与仅用TBI预处理的受体细胞相比,宿主骨髓中的T细胞和NK细胞显著减少。CyP延迟了宿主胸腺细胞的再填充,为在成熟T细胞产生之前建立供体嵌合体提供了时间。嵌合动物表现出稳定的多谱系嵌合体以及对皮肤移植的供体特异性耐受,且在体外试验中也是如此。该模型可能为诱导供体特异性移植耐受提供一种临床可接受的方法。